Blue Earth Therapeutics Strengthens Ties With Seibersdorf Labor

Blue Earth Therapeutics Ltd, a subsidiary of Bracco focused on advancing next-generation therapeutic radiopharmaceuticals, has broadened its manufacturing partnership with Seibersdorf Labor GmbH. This expanded agreement now encompasses the production of the investigational 225Ac-based radioligand therapy, ensuring future supply for clinical trial sites in the UK, EU, and the U.S. The investigational drug, (225Ac) rhPSMA‐10.1, is a radiohybrid Prostate‐Specific Membrane Antigen (rhPSMA)-targeted therapeutic radiopharmaceutical. It is the second candidate in Blue Earth’s oncology pipeline, aimed at developing cutting-edge radiopharmaceutical treatments.

David E. Gauden, DPhil., Chief Executive Officer of Blue Earth Therapeutics Ltd., “We are very pleased to add manufacture of our 225Ac-based investigational product to our partnership with Seibersdorf Labor. It has the potential to be a product of high purity and stability, and this partnership will enable supply of the clinical trial sites in London, and other regions if necessary. Seibersdorf has been an excellent and collaborative partner, and we look forward to working with them on many more projects in the future.”

Dr. Markus Neumann, Managing Director of Seibersdorf Labor GmbH, also added “This is our first project using the 225Ac radioisotope and we have implemented dedicated infrastructure and services to support it. We are excited to take on the challenge of developing in-house expertise for 225Ac and expand our projects with Blue Earth Therapeutics to include this new agent and look forward to delivering doses to treat patients in clinical trials. Blue Earth Therapeutics has been a very supportive partner as we expand our capabilities, and we are proud to be part of their network.”